Search
for
Sort by
Research 31–60 of 1000+
- Bempikibart shows its potential for hair regrowth in alopecia areata
- Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
- 724 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin in adults with severe to very-severe alopecia areata
- Real‐world effectiveness and safety of tofacitinib for alopecia areata: A retrospective cohort study of 202 patients
- Determining meaningful thresholds for evaluating treatment efficacy in patients with alopecia areata
- Effectiveness and safety of baricitinib in patients with moderate‐to‐severe refractory alopecia areata in real world: An open‐label, single‐center study
- 44047 Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
- Evaluation of Hair Regrowth after Minoxidil and Dutasteride Tattooing in Men with Androgenetic Alopecia
- Efficacy and safety of azathioprine in alopecia areata
- P152 : Association between degrees of alopecia and prostate specific antigen level in men with androgenetic alopecia
- Effectiveness and safety of Baricitinib in alopecia areata: a prospective cohort study
- Immune signatures of psoriasis: Comparison of genetic expression profiles in psoriasis patients after therapy with biologic agents
- Impact of ustekinumab on quality of life and sexual difficulties associated with psoriasis: Results from phase III clinical trials
- Efficacy and predictive markers of response to tofacitinib and baricitinib therapy in alopecia areata: A 52-week comparative cohort study
- Evaluation of serum vitamin D3 before and after intralesional injection of vitamin D3 in patients with alopecia areata
- Circulating monocytes as a marker of response to adalimumab in patients with hidradenitis suppurativa
- Association between degrees of alopecia and prostate specific antigen level in men with androgenetic alopecia
- Tissue Retinol‐Binding Protein 4 Expression and Its Genetic Variants (rs3758539) in Patients With Severe and Treatment‐Refractory Alopecia Areata: Association With Response to Baricitinib
- Testosterone target therapy: focus on immune response, controversies and clinical implications in patients with COVID-19 infection
- Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study
- Uses of Dupilumab in Dermatology: A Systematic Review of the Randomized Controlled Trials
- Microneedling with Triamcinolone acetonide versus Intralesional Triamcinolone acetonide in treatment of Alopecia Areata
- 341 A longitudinal study of cutaneous dermatomyositis
- Concordance between clinician-reported and patient-reported outcomes of eyebrow and eyelash hair loss in patients with severe alopecia areata: Results from BRAVE-AA1 and BRAVE-AA2 studies
- Injectable Platelet-, Leukocyte-, and Fibrin-Rich Plasma (iL-PRF) in the Management of Androgenetic Alopecia
- Efficacy of different doses of Platelet-Rich Plasma for Moderate Carpal Tunnel Syndrome:Study Protocol for a Prospective, Randomized, Controlled trail
- How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
- Evidence-Based Data on How Long to Treat to Achieve Treatment Response With Baricitinib in Severe Alopecia Areata
- 42227 Efficacy and Predictive Factors of Systemic Corticosteroid in Alopecia Areata: Reappraisal of Oral Methylprednisolone Tapering Treatment
- 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata